Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

L'Oreal slumps as Q4 sales miss expectations

(Sharecast News) - L'Oreal shares slumped on Friday after the cosmetics group posted lower-than-expected fourth-quarter sales. In results released on Thursday, the company said fourth-quarter sales rose 6.9% on a like-for-like basis to €10.61bn, missing expectations of €10.9bn. On a reported basis, sales were up 2.8%.

On a LFL basis, sales were up 11.6% in Europe and 9.4% in North America, but down 6.2% in North Asia, which continued to be dented by market softness in mainland China and "the reset in travel retail" following the change in policy regarding 'daigous'.

Daigous refers to the process by which agents buy luxury goods abroad to avoid taxes and resell them in China.

For the full year 2023, sales grew 7.6% on a reported basis and 11% on a LFL basis to €41.18bn.

Chief executive Nicolas Hieronimus said: "In a challenging environment of geopolitical tensions, inflationary pressures, and a stagnating beauty market in China, we delivered our best like-for-like growth in more than 20 years (excluding 2021).

"This is a clear vindication of the power of our multi-polar model, and I am particularly pleased with the strong acceleration in emerging markets."

At 1030 GMT, the shares were down 5.6% at €427.65.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.